TYK2TYK2

Back to Disease

June 2026

Medication Review: Deucravacitinib Dosing, Administration, DDIs, & Safety in Clinical Practice

July 2026

RhAPPcast: Treat-to-Target in SLE: DORIS Remission Real in Practice

May 2026

FAQ: TYK2/STAT Signaling: The Immunologic Rationale for TYK2 Therapy in SLE & Sjögren’s Disease

May 2026

FAQ: What Is Minimal Disease Activity in PsA and How Does Deucravacitinib Perform at 52 Weeks?

June 2025

Journal Club Review: A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis

June 2026

RhAPPcast: TYK2 Inhibition in PsA, Sjögren’s and SLE: What APPs Need to Know as Future Uses Emerge

December 2025

Medication Review: What Is the Safety Profile of Deucravacitinib in PsO and PsA?

December 2025

Medication Review: What is the Mechanism of Action of Deucravacitinib?

December 2025

FAQ: TYK2/STAT Pathway & Why TYK2 Therapy Works for Psoriasis and Psoriatic Arthritis

June 2025

FAQ: How Does the Selectivity of TYK2 and JAK Enzyme Inhibition Influence Their Safety Profiles

sectionimg

dotsimg

Download the app and start using it now.

Download on the App Store

GET IT ON Google Play